I agree. I have no idea about Parkinson's data. I didn't invest in Anavex for Rett or Parkinsons or anything other than Alzheimers. My fear is that poor PDD or Rett results may be a canary in the coal mine for the Alzheimer's data but it works the other way too. If good data is released then people will presume the future data for Alzheimers will be good too.
I also don't put much stock in Dr. Missling, or his timelines. Most things take longer than planned and Dr. Missling has a habit of overpromising and underdelivering, time and again, to the point where I am surprised the market actually thought data would be released today?
No reputable company releases data on a financial conference call. The people attending today's meeting have a cursory background in science, at best. They're financial analysts, MBA and CFAs -- if Missling had revolutionary breakthrough data he would want to release it in front of MDs and PhDs.
So, I wouldn't be surprised to not get the data until there's another major Parkinson's conference. I also have to wonder how efficient the data processing is right now during this pandemic. If he said mid-year, was that before everything got crazy? As you all know I am far from a Missling apologist, but when it comes to deadlines during a pandemic even I think it's only fair to cut him some slack. He probably wouldn't have released the data on time anyway but at least now there's a valid excuse.
This is the same company today that it was yesterday, and the week before, and the year before. I still think its market cap is a bit overvalued at the moment, but what we say yesterday is just a small glimpse into how much this stock will move once Phase 3 data is released for Alzheimer's. Which direction it runs is anyone's guess but the stock is going to move sharply, and all today's price action is about is placing bets on who will be right, shorts or longs.
